Wells Fargo cuts Kimberly-Clark stock price target on earnings concerns

Wells Fargo cut Kimberly-Clark's price target to $105 from $110 while retaining an Equal Weight rating, citing new North American competition, China headwinds and a plausible 2026 guidance cut; KMB traded at $98.70, down 7.5% over the prior week. The firm said the EPS outlook is less anchored, with 13 analysts having reduced upcoming earnings estimates. Kimberly-Clark's Q2 adjusted EPS beat estimates at $2.12 versus $2.01, but revenue missed at $4.19B versus $4.23B, while the planned KVUE transaction requires base growth and above-average synergies.

Analysis

The key equity risk is not the next-quarter miss but a reset in the earnings algorithm just as KMB needs to demonstrate that the KVUE transaction can be funded by durable organic growth rather than cost extraction. Incremental North American competition raises promotion and shelf-space-defense risk, while China weakness removes a potential offset; together, this can force a choice between volume retention and gross-margin protection. That tradeoff is particularly damaging for a staples multiple because it lowers confidence in both the earnings base and the pace of deleveraging/synergy realization after closing.

Over the next 1-3 months, estimate reductions and any management commentary that narrows the outlook range are likely more important than the current valuation discount. KMB can look optically cheap while the denominator continues to fall; a guidance cut would also pressure the market's willingness to capitalize KVUE synergies at full value. Conversely, independently observable NielsenIQ improvement in core North American categories, stabilization in China, and confirmation that promotional intensity is contained would make the recent selloff more likely to represent a tradable overshoot.

KVUE is a second-order beneficiary only if the transaction closes on schedule and KMB preserves financial flexibility; its standalone valuation should not fully price an acquirer synergy narrative until financing, regulatory, and integration milestones are clearer. A contrarian view is that category exposure to health and beauty can prove more resilient than broad staples data suggest, making a modest KMB reset sufficient rather than a prolonged impairment. The falsification point for the bearish KMB thesis is a maintained full-year framework alongside sequential volume/mix acceleration and no evidence of incremental trade-spend pressure.

Key Decisions for Investors

• Maintain a 1-3 month underweight/short bias in KMB versus XLP or PG rather than an outright large short. Add only on a failed rebound into the $103-$105 area or after formal guidance/estimate cuts; cover if management reaffirms the full-year framework with improving North American scanner data. Target a retest of the recent low-to-mid $90s, with risk defined by a sustained move above $108.
• Use a relative-value pair: long KVUE / short KMB in roughly beta-neutral sizing through the expected closing and integration-update window. The thesis is that KMB bears execution, promotional, and financing-risk perception while KVUE retains transaction support; exit if closing timing slips, antitrust issues emerge, or KMB discloses materially better-than-expected synergy economics.
• Do not buy KMB solely on apparent undervaluation before the next guidance checkpoint. Set an alert for consensus EPS revisions flattening and two consecutive periods of stable-to-improving volume/mix; absent those data, the discount is more likely compensation for a declining earnings anchor than a margin-of-safety signal.
• For defined-risk bearish exposure into the next earnings/guidance event, consider KMB 2-3 month put spreads only if implied volatility remains below the likely move implied by a guidance-reset scenario. A $100/$92.50 structure limits upside risk while targeting the valuation gap that could open if consensus 2026 EPS is reduced; avoid if options already price a high-single-digit downside move.